Skip to main content
![Creative Commons 'BY' version 4.0 license]()
AMSA therapy for children with lymphoblastic malignancy.
Abstract
AMSA is an acriflavine derivative that inhibits DNA synthesis. Preliminary studies have suggested that AMSA is an active drug in patients with acute myelogenous leukemia and acute lymphoblastic leukemia (ALL). This report describes the response and toxic reactions observed in children with refractory ALL or lymphoblastic lymphoma who were treated with AMSA.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.